Anebulo Pharmaceuticals (NASDAQ:ANEB) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its quarterly earnings data on Friday. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08, FiscalAI reports.

Anebulo Pharmaceuticals Stock Performance

NASDAQ ANEB opened at $0.48 on Friday. Anebulo Pharmaceuticals has a 52 week low of $0.44 and a 52 week high of $3.42. The stock’s 50 day moving average price is $1.24 and its two-hundred day moving average price is $2.04. The stock has a market capitalization of $19.68 million, a price-to-earnings ratio of -2.52 and a beta of -0.81.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. acquired a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 28.40% of the company’s stock.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.